vs
Esperion Therapeutics, Inc.（ESPR）与JFrog Ltd（FROG）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是JFrog Ltd的1.2倍（$168.4M vs $145.3M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 25.2%），过去两年JFrog Ltd的营收复合增速更高（20.4% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
JFrog Ltd是全球知名的DevOps技术服务商，面向科技、金融、零售、制造等多个行业客户，提供全链路软件发布、制品管理与安全解决方案，助力企业简化云、本地及混合部署环境下的应用开发与交付流程。
ESPR vs FROG — 直观对比
营收规模更大
ESPR
是对方的1.2倍
$145.3M
营收增速更快
ESPR
高出118.5%
25.2%
两年增速更快
FROG
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $145.3M |
| 净利润 | — | $-15.2M |
| 毛利率 | — | 77.9% |
| 营业利润率 | 50.6% | -14.7% |
| 净利率 | — | -10.5% |
| 营收同比 | 143.7% | 25.2% |
| 净利润同比 | — | 34.4% |
| 每股收益（稀释后） | $0.32 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRFROG
| Q4 25 | $168.4M | $145.3M | ||
| Q3 25 | $87.3M | $136.9M | ||
| Q2 25 | $82.4M | $127.2M | ||
| Q1 25 | $65.0M | $122.4M | ||
| Q4 24 | $69.1M | $116.1M | ||
| Q3 24 | $51.6M | $109.1M | ||
| Q2 24 | $73.8M | $103.0M | ||
| Q1 24 | $137.7M | $100.3M |
净利润ESPRFROG
| Q4 25 | — | $-15.2M | ||
| Q3 25 | $-31.3M | $-16.4M | ||
| Q2 25 | $-12.7M | $-21.7M | ||
| Q1 25 | $-40.5M | $-18.5M | ||
| Q4 24 | — | $-23.2M | ||
| Q3 24 | $-29.5M | $-22.9M | ||
| Q2 24 | $-61.9M | $-14.3M | ||
| Q1 24 | $61.0M | $-8.8M |
毛利率ESPRFROG
| Q4 25 | — | 77.9% | ||
| Q3 25 | — | 77.4% | ||
| Q2 25 | — | 76.3% | ||
| Q1 25 | — | 75.3% | ||
| Q4 24 | — | 75.4% | ||
| Q3 24 | — | 75.0% | ||
| Q2 24 | — | 78.8% | ||
| Q1 24 | — | 79.5% |
营业利润率ESPRFROG
| Q4 25 | 50.6% | -14.7% | ||
| Q3 25 | -11.4% | -15.8% | ||
| Q2 25 | 8.6% | -20.4% | ||
| Q1 25 | -34.0% | -18.8% | ||
| Q4 24 | -6.4% | -21.9% | ||
| Q3 24 | -31.0% | -27.4% | ||
| Q2 24 | 3.5% | -18.6% | ||
| Q1 24 | 52.5% | -16.6% |
净利率ESPRFROG
| Q4 25 | — | -10.5% | ||
| Q3 25 | -35.9% | -12.0% | ||
| Q2 25 | -15.4% | -17.0% | ||
| Q1 25 | -62.2% | -15.1% | ||
| Q4 24 | — | -20.0% | ||
| Q3 24 | -57.2% | -21.0% | ||
| Q2 24 | -83.9% | -13.9% | ||
| Q1 24 | 44.3% | -8.8% |
每股收益（稀释后）ESPRFROG
| Q4 25 | $0.32 | $-0.13 | ||
| Q3 25 | $-0.16 | $-0.14 | ||
| Q2 25 | $-0.06 | $-0.19 | ||
| Q1 25 | $-0.21 | $-0.16 | ||
| Q4 24 | $-0.14 | $-0.21 | ||
| Q3 24 | $-0.15 | $-0.21 | ||
| Q2 24 | $-0.33 | $-0.13 | ||
| Q1 24 | $0.34 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $704.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $887.4M |
| 总资产 | $465.9M | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRFROG
| Q4 25 | $167.9M | $704.4M | ||
| Q3 25 | $92.4M | $651.1M | ||
| Q2 25 | $86.1M | $611.7M | ||
| Q1 25 | $114.6M | $563.5M | ||
| Q4 24 | $144.8M | $522.0M | ||
| Q3 24 | $144.7M | $467.8M | ||
| Q2 24 | $189.3M | $591.3M | ||
| Q1 24 | $226.6M | $579.6M |
股东权益ESPRFROG
| Q4 25 | $-302.0M | $887.4M | ||
| Q3 25 | $-451.4M | $859.4M | ||
| Q2 25 | $-433.5M | $826.5M | ||
| Q1 25 | $-426.2M | $800.0M | ||
| Q4 24 | $-388.7M | $773.5M | ||
| Q3 24 | $-370.2M | $756.2M | ||
| Q2 24 | $-344.2M | $721.4M | ||
| Q1 24 | $-294.3M | $707.8M |
总资产ESPRFROG
| Q4 25 | $465.9M | $1.3B | ||
| Q3 25 | $364.0M | $1.3B | ||
| Q2 25 | $347.1M | $1.2B | ||
| Q1 25 | $324.0M | $1.2B | ||
| Q4 24 | $343.8M | $1.1B | ||
| Q3 24 | $314.1M | $1.1B | ||
| Q2 24 | $352.3M | $1.0B | ||
| Q1 24 | $373.1M | $997.1M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $50.7M |
| 自由现金流经营现金流 - 资本支出 | — | $49.9M |
| 自由现金流率自由现金流/营收 | — | 34.3% |
| 资本支出强度资本支出/营收 | 0.0% | 0.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $142.3M |
8季度趋势，按日历期对齐
经营现金流ESPRFROG
| Q4 25 | $45.2M | $50.7M | ||
| Q3 25 | $-4.3M | $30.2M | ||
| Q2 25 | $-31.4M | $36.1M | ||
| Q1 25 | $-22.6M | $28.8M | ||
| Q4 24 | $-35.0M | $49.1M | ||
| Q3 24 | $-35.3M | $27.6M | ||
| Q2 24 | $-7.2M | $16.7M | ||
| Q1 24 | $53.8M | $17.5M |
自由现金流ESPRFROG
| Q4 25 | — | $49.9M | ||
| Q3 25 | — | $28.8M | ||
| Q2 25 | — | $35.5M | ||
| Q1 25 | — | $28.1M | ||
| Q4 24 | — | $48.5M | ||
| Q3 24 | $-35.5M | $26.7M | ||
| Q2 24 | $-7.3M | $16.0M | ||
| Q1 24 | $53.8M | $16.6M |
自由现金流率ESPRFROG
| Q4 25 | — | 34.3% | ||
| Q3 25 | — | 21.0% | ||
| Q2 25 | — | 27.9% | ||
| Q1 25 | — | 23.0% | ||
| Q4 24 | — | 41.8% | ||
| Q3 24 | -68.7% | 24.5% | ||
| Q2 24 | -9.9% | 15.5% | ||
| Q1 24 | 39.0% | 16.6% |
资本支出强度ESPRFROG
| Q4 25 | 0.0% | 0.6% | ||
| Q3 25 | 0.0% | 1.0% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.0% | 0.5% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.3% | 0.9% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 0.1% | 0.8% |
现金转化率ESPRFROG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
FROG
暂无分部数据
